Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)
Historic Debt Ratio for Inhibikase Therapeutics (IKT) over the last 6 years, with Q2 2025 value amounting to 0.0.
- Inhibikase Therapeutics' Debt Ratio fell 9752.38% to 0.0 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.0, marking a year-over-year decrease of 9752.38%. This contributed to the annual value of 0.0 for FY2024, which is 8916.69% down from last year.
- Per Inhibikase Therapeutics' latest filing, its Debt Ratio stood at 0.0 for Q2 2025, which was down 9752.38% from 0.0 recorded in Q1 2025.
- Over the past 5 years, Inhibikase Therapeutics' Debt Ratio peaked at 0.03 during Q3 2024, and registered a low of 0.0 during Q2 2025.
- For the 5-year period, Inhibikase Therapeutics' Debt Ratio averaged around 0.01, with its median value being 0.01 (2022).
- As far as peak fluctuations go, Inhibikase Therapeutics' Debt Ratio surged by 29805.51% in 2024, and later crashed by 9752.38% in 2025.
- Inhibikase Therapeutics' Debt Ratio (Quarter) stood at 0.01 in 2021, then grew by 15.64% to 0.01 in 2022, then soared by 76.92% to 0.01 in 2023, then plummeted by 89.17% to 0.0 in 2024, then tumbled by 61.9% to 0.0 in 2025.
- Its Debt Ratio stands at 0.0 for Q2 2025, versus 0.0 for Q1 2025 and 0.0 for Q4 2024.